Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Biora Therapeutics, Inc.

Biora Therapeutics is reimagining therapeutics by creating smart pills designed for 
- targeted drug delivery to the GI tract, and 
- systemic, needle-free delivery of biotherapeutics
we are developing therapies to improve patients’ lives. 

At Biora, we envision a world where patients have access to needle-free drug delivery and better therapeutic outcomes. We welcome you to learn more about our mission and our guiding principles at https://bioratherapeutics.com/company/about

Biora Therapeutics

Biora Therapeutics Q3 corporate update to be held on November 13: https://lnkd.in/dm7wYB5J

Biora Therapeutics presents new data on the BioJet platform at #EASD2023 https://lnkd.in/gfRHf8gJ 
#drugdelivery

Biora Therapeutics announces submission of IND application to the FDA for BT-600 program https://lnkd.in/d26etYKu #IBD #UC #ulcerativecolitis

Dr. Shaoying Nikki Lee presented data from the NaviCap™ targeted oral delivery platform to IBD researchers at the Crohn's & Colitis Foundation Researcher Symposium in New York City this week. #IBD #ulcerativecolitis #drugdelivery

Biora Therapeutics progresses its BioJet™ systemic oral delivery platform https://lnkd.in/gx8NfFwz #oraldelivery #biologics #needlefree #drugdelivery

Biora Therapeutics provides corporate update and reports second quarter 2023 financial results: https://lnkd.in/gQWCHdKe

Announcing successful clinical device performance study results for our NaviCap™ targeted oral delivery platform #IBD #UC #ulcerativecolitis  https://lnkd.in/e7fqQSvx

See this week's feature in the San Diego Business Journal highlighting our BioJet™ systemic delivery platform: https://lnkd.in/gYDTAWDK #oraldelivery #biologics #needlefree
#drugdelivery

Biora Therapeutics announces new patents for its NaviCap™ targeted oral delivery platform  https://lnkd.in/gpD-xZnf #IP

Congrats to the authors who were at the American Diabetes Association sharing bioavailability data for orally-delivered GLP-1 receptor agonist. If you haven't seen the poster yet, download it here:  https://lnkd.in/gR_S6biY #ADA2023 #oraldelivery #biologics #needlefree
#drugdelivery

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	127.97M -	143.99M 12.51%	74.31M 48.39%	1.25M 98.32%	305K 75.54%	4K 98.69%
cost of revenue	92.08M -	100.49M 9.14%	93.43M 7.02%
gross profit	35.90M -	43.49M 21.16%	-19.12M 143.96%	1.25M 106.52%	305K 75.54%	4K 98.69%
selling and marketing expenses	50.19M -	58.89M 17.34%	52.89M 10.19%	4.76M 91.00%
general and administrative expenses	51.24M -	61.32M 19.68%	75.44M 23.02%	68.54M 9.14%
selling general and administrative expenses	101.42M -	120.21M 18.52%	128.32M 6.75%	73.30M 42.88%	38.04M 48.11%	37.31M 1.91%
research and development expenses	48.71M -	63.40M 30.15%	47.74M 24.70%	45.78M 4.10%	24.05M 47.47%	29.84M 24.07%
other expenses				5.99M -	2.62M 56.31%
cost and expenses	242.21M -	284.10M 17.30%	269.50M 5.14%	119.08M 55.81%	62.09M 47.86%	67.15M 8.15%
operating expenses	150.14M -	183.61M 22.30%	176.07M 4.11%	119.08M 32.36%	62.09M 47.86%	67.15M 8.15%
interest expense	9.09M -	9.20M 1.19%	34.87M 279.08%	-12.64M 136.24%	10.99M 186.97%	9.81M 10.69%
ebitda	-108.69M -	-133.19M 22.54%	-195.19M 46.54%	-63.68M 67.38%	-59.16M 7.09%	-66.92M 13.12%
operating income	-114.24M -	-140.12M 22.65%	-195.19M 39.30%	-117.84M 39.63%	-61.78M 47.57%	-67.14M 8.68%
depreciation and amortization	6.07M -	6.92M 14.01%	5.06M 26.94%	54.16M 970.51%	2.62M 95.17%	219K 91.63%
total other income expenses net	-2.33M -	-8.62M 270.61%	-34.87M 304.36%	-60.80M 74.36%	12.53M 120.61%	-57.28M 557.11%
income before tax	-123.86M -	-148.74M 20.09%	-230.06M 54.67%	-178.64M 22.35%	-49.25M 72.43%	-124.42M 152.64%
income tax expense	5.25M -	-706K 113.45%	-37.53M 5,216.15%	-119K 99.68%	-420K 252.94%	-90K 78.57%
net income	-129.11M -	-148.04M 14.66%	-192.53M 30.05%	-178.52M 7.28%	-48.83M 72.65%	-124.11M 154.18%
weighted average shs out	1.08M -	1.40M 30.05%	1.10M 21.53%	3.85M 249.49%	7.64M 98.51%	15.77M 106.59%
weighted average shs out dil	1.08M -	1.40M 30.05%	1.10M 21.53%	3.85M 249.49%	7.64M 98.51%	15.77M 106.59%
eps	-119.71 -	-105.55 11.83%	-174.94 65.74%	-46.42 73.47%	-6.40 86.21%	-7.87 22.97%
epsdiluted	-119.71 -	-105.55 11.83%	-174.94 65.74%	-46.42 73.47%	-6.40 86.21%	-7.87 22.97%

COM:BIORATHERAPEUTICS

Biora Therapeutics, Inc.

Last Close

1.63

22/11 21:00

Market Cap

23.40M

Beta: -

Volume Today

82.22K

Avg: -

Preview